Kochang

Researchers are evaluating the drug CMG190303 for treating adults with Type 2 Diabetes and Dyslipidemia. This phase III trial aims to compare how CMG190303 affects blood sugar control measured by HbA1c and cholesterol levels measured by LDL-C over 24 weeks, compared to two other treatments Rosuvastatin and Dapagliflozin. The study also monitors the safety of CMG190303 throughout the treatment period. Participants are randomly assigned to one of three groups those receiving CMG190303 a combination of Dapagliflozin and Rosuvastatin with doses increasing over 24 weeks, a group receiving Dapagliflozin with a Rosuvastatin placebo, or a group receiving Rosuvastatin with a Dapagliflozin placebo. The dosing schedule adjusts every 8 weeks with increasing amounts for both drugs in the CMG190303 group, while the placebo groups maintain consistent dosing. The trial is double-blinded, meaning neither participants nor researchers know which treatment is given. During the study, participants will have regular assessments to measure their HbA1c and LDL-C levels at various points up to 24 weeks. Additional blood tests will monitor fasting plasma glucose and other lipid parameters at 8, 16, and 24 weeks. Medication adherence is tracked, and safety monitoring is ongoing. The total participation duration is 24 weeks of treatment, during which researchers collect data to understand the drugs effects and safety in adults with these conditions.

Researchers are observing the long-term clinical outcomes of patients with unprotected left main coronary artery LMCA disease. This study aims to compare the results of three treatment approaches medical therapy, coronary stenting with drug-eluting stents DES, and coronary artery bypass grafting CABG in real-world daily practice. The study collects data from multiple centers across Korea and the Asia-Pacific region to better understand treatment effects in routine care settings. This multicenter registry will enroll approximately 5000 patients diagnosed with significant unprotected LMCA stenosis over 50% blockage by visual estimation. Participants will be followed prospectively to record their treatment courses and outcomes. The study does not assign treatments but observes patients undergoing medical therapy, PCI with DES, or CABG as decided by their doctors. Participants will be monitored for up to 10 years, with key outcomes including death, heart attacks, repeat vessel procedures, and cerebrovascular events. The primary outcome is a composite event rate measured at 2 years. Additional assessments include stent-related complications and rehospitalizations. Data collection will involve regular clinical follow-ups to capture these health events and understand the long-term effects of different treatment approaches.